Evidence map›Paper›PMID 39577887›Full record

ReviewAdvances in kidney disease and health2024

Nephrolithiasis.

Megan L Prochaska, Anna L Zisman

Abstract readReviewCase Reports
In one paragraph

Review in Advances in kidney disease and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Megan L ProchaskaDepartment of Medicine, Section of Nephrology, University of Chicago Pritzker School of Medicine, Chicago, IL.
Anna L ZismanDepartment of Medicine, Section of Nephrology, University of Chicago Pritzker School of Medicine, Chicago, IL. Electronic address: azisman@bds.uchicago.edu.

Funding

Mechanisms of disordered citrate and oxalate excretion in nephrolithiasisK23DK127252 · NIDDK · UNIVERSITY OF CHICAGO · PI PROCHASKA, MEGAN L · 2022 to 2025
$744k
NIDDK NIH HHS K23 DK127252
6 · The paper itself

Abstract

Kidney stone prevalence is rapidly increasing worldwide, and decreasing stone growth and recurrence is critical to reducing morbidity. Preventative approaches vary with kidney stone type, so knowledge of stone composition and a thorough history and metabolic evaluation are necessary to individualize therapy. The cases presented herein highlight treatment strategies for the most common stone types seen in clinical practice with practical pearls for the nephrologist.

Indexed as

NephrolithiasisHumansKidney CalculiLithotripsy

Identifiers

PMID39577887
PMCPMC13561066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.